Major Shareholder Converts Preferred Stock to 6.65% Common Stake Amidst Merger Activity
GRTX has more than doubled off its 52-week low of $0.015.
Summary
A major shareholder converted preferred stock into a 6.65% common equity stake, valued at over $1.1 million, and committed to supporting the company's pending merger with Obsidian Therapeutics.
Key Events · Ownership and Investor Activity · GRTX
-
Preferred Stock Conversion
Parvinder Singh Hyare converted 13,521.292 shares of Series B Non-Voting Convertible Preferred Stock into 13,521,921 shares of common stock, effective May 15, 2026.
-
Significant Common Stock Holding
Following the mandatory conversion, Mr. Hyare beneficially owns 13,521,921 shares of common stock, representing approximately 6.65% of the outstanding shares.
-
Support for Obsidian Merger
Mr. Hyare is party to a Stockholder Support Agreement, committing to vote all eligible shares in favor of the definitive merger agreement with Obsidian Therapeutics.
-
Context of Prior Mergers
The Series B Preferred Stock originated from the Nova Pharmaceuticals merger in December 2024, and this conversion is a step in the company's ongoing capital structure adjustments amidst its pending merger with Obsidian Therapeutics.
Analysis · GRTX · Life Sciences
Parvinder Singh Hyare, a significant shareholder, converted 13,521.292 shares of Series B Preferred Stock into 13,521,921 shares of common stock, representing 6.65% of the company. This conversion, valued at over $1.1 million based on current prices, makes his substantial stake more liquid. The filing also confirms his support for the pending merger with Obsidian Therapeutics, which is a critical step for the company's future given its ongoing going concern warnings.
At the time of this filing, GRTX was trading at $0.09 on OTC in the Life Sciences sector, with a market capitalization of approximately $13.6M. The 52-week trading range was $0.02 to $0.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.